1h Free Analyst Time
The publisher's latest Pharmaceutical and Healthcare disease pipeline guide Influenza A Virus, H3N2 Subtype Infections - Drugs In Development, 2021, provides an overview of the Influenza A Virus, H3N2 Subtype Infections (Infectious Disease) pipeline landscape.Speak directly to the analyst to clarify any post sales queries you may have.
H3N2 infections are caused by variant H3N2 virus which is an influenza virus. Symptoms include cough, sore throat, runny or stuffy nose, chills, nausea, vomiting, and/or diarrhea. Risk factors include age, chronic medical conditions like asthma, diabetes, heart disease, weakened immune systems, and neurological or neurodevelopment conditions. Treatment includes antiviral medications and antibiotics.
Report Highlights
The publisher's Pharmaceutical and Healthcare latest pipeline guide Influenza A Virus, H3N2 Subtype Infections - Drugs In Development, 2021, provides comprehensive information on the therapeutics under development for Influenza A Virus, H3N2 Subtype Infections (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Influenza A Virus, H3N2 Subtype Infections (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Influenza A Virus, H3N2 Subtype Infections and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 6, 7, 9, 5, 15 and 4 respectively. Similarly, the Universities portfolio in Phase III and Preclinical stages comprises 3 and 3 molecules, respectively.
Influenza A Virus, H3N2 Subtype Infections (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Influenza A Virus, H3N2 Subtype Infections (Infectious Disease).
- The pipeline guide reviews pipeline therapeutics for Influenza A Virus, H3N2 Subtype Infections (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Influenza A Virus, H3N2 Subtype Infections (Infectious Disease) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Influenza A Virus, H3N2 Subtype Infections (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Influenza A Virus, H3N2 Subtype Infections (Infectious Disease)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Influenza A Virus, H3N2 Subtype Infections (Infectious Disease).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Influenza A Virus, H3N2 Subtype Infections (Infectious Disease) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
IntroductionInfluenza A Virus, H3N2 Subtype Infections - Overview
- Influenza A Virus, H3N2 Subtype Infections - Therapeutics Development
Influenza A Virus, H3N2 Subtype Infections - Companies Involved in Therapeutics Development
Influenza A Virus, H3N2 Subtype Infections - Drug Profiles
Influenza A Virus, H3N2 Subtype Infections - Dormant Projects
Influenza A Virus, H3N2 Subtype Infections - Discontinued Products
Influenza A Virus, H3N2 Subtype Infections - Product Development Milestones
Appendix
List of Tables
- Number of Products under Development for Influenza A Virus, H3N2 Subtype Infections, 2021
- Number of Products under Development by Companies, 2021
- Number of Products under Development by Universities/Institutes, 2021
- Products under Development by Companies, 2021
- Products under Development by Universities/Institutes, 2021
- Number of Products by Stage and Target, 2021
- Number of Products by Stage and Mechanism of Action, 2021
- Number of Products by Stage and Route of Administration, 2021
- Number of Products by Stage and Molecule Type, 2021
- Influenza A Virus, H3N2 Subtype Infections - Pipeline by AbbVie Inc, 2021
- Influenza A Virus, H3N2 Subtype Infections - Pipeline by Adimmune Corp, 2021
- Influenza A Virus, H3N2 Subtype Infections - Pipeline by Alla Chem LLC, 2021
- Influenza A Virus, H3N2 Subtype Infections - Pipeline by Allergy Therapeutics Plc, 2021
- Influenza A Virus, H3N2 Subtype Infections - Pipeline by AlphaVax Inc, 2021
- Influenza A Virus, H3N2 Subtype Infections - Pipeline by Ansun Biopharma Inc, 2021
- Influenza A Virus, H3N2 Subtype Infections - Pipeline by Aphios Corp, 2021
- Influenza A Virus, H3N2 Subtype Infections - Pipeline by AstraZeneca Plc, 2021
- Influenza A Virus, H3N2 Subtype Infections - Pipeline by AusBio Ltd, 2021
- Influenza A Virus, H3N2 Subtype Infections - Pipeline by BiondVax Pharmaceuticals Ltd, 2021
- Influenza A Virus, H3N2 Subtype Infections - Pipeline by BlueWillow Biologics Inc, 2021
- Influenza A Virus, H3N2 Subtype Infections - Pipeline by Brandenburg Antiinfektiva GmbH, 2021
- Influenza A Virus, H3N2 Subtype Infections - Pipeline by Celltrion Inc, 2021
- Influenza A Virus, H3N2 Subtype Infections - Pipeline by Changchun Bcht Biotechnology Co Ltd, 2021
- Influenza A Virus, H3N2 Subtype Infections - Pipeline by Chicago Biosolutions Inc, 2021
- Influenza A Virus, H3N2 Subtype Infections - Pipeline by Cidara Therapeutics Inc, 2021
- Influenza A Virus, H3N2 Subtype Infections - Pipeline by CSL Ltd, 2021
- Influenza A Virus, H3N2 Subtype Infections - Pipeline by Emergent BioSolutions Inc, 2021
- Influenza A Virus, H3N2 Subtype Infections - Pipeline by FluGen Inc, 2021
- Influenza A Virus, H3N2 Subtype Infections - Pipeline by Gamma Vaccines Pty Ltd, 2021
- Influenza A Virus, H3N2 Subtype Infections - Pipeline by ILiAD Biotechnologies LLC, 2021
- Influenza A Virus, H3N2 Subtype Infections - Pipeline by Inovio Pharmaceuticals Inc, 2021
- Influenza A Virus, H3N2 Subtype Infections - Pipeline by Institute of Virology Vaccines and Sera Torlak, 2021
- Influenza A Virus, H3N2 Subtype Infections - Pipeline by InvVax Inc, 2021
- Influenza A Virus, H3N2 Subtype Infections - Pipeline by Jiangsu Ab&b Biotechnology Co Ltd, 2021
- Influenza A Virus, H3N2 Subtype Infections - Pipeline by Jiangsu Kanion Pharmaceutical Co Ltd, 2021
- Influenza A Virus, H3N2 Subtype Infections - Pipeline by Liaoning Cheng Da Biotechnology Co Ltd, 2021
- Influenza A Virus, H3N2 Subtype Infections - Pipeline by Medicago Inc, 2021
- Influenza A Virus, H3N2 Subtype Infections - Pipeline by NanoViricides Inc, 2021
- Influenza A Virus, H3N2 Subtype Infections - Pipeline by New Amsterdam Sciences Inc, 2021
- Influenza A Virus, H3N2 Subtype Infections - Pipeline by Novavax Inc, 2021
- Influenza A Virus, H3N2 Subtype Infections - Pipeline by PrEP Biopharm Ltd, 2021
- Influenza A Virus, H3N2 Subtype Infections - Pipeline by Sanofi, 2021
- Influenza A Virus, H3N2 Subtype Infections - Pipeline by Sciogen Inc, 2021
- Influenza A Virus, H3N2 Subtype Infections - Pipeline by Seqirus Ltd, 2021
- Influenza A Virus, H3N2 Subtype Infections - Pipeline by Serum Institute of India Pvt Ltd, 2021
- Influenza A Virus, H3N2 Subtype Infections - Pipeline by Shanghai Institute of Biological Products Co Ltd, 2021
- Influenza A Virus, H3N2 Subtype Infections - Pipeline by Trellis Bioscience Inc, 2021
- Influenza A Virus, H3N2 Subtype Infections - Pipeline by Vacthera BioTech GmbH, 2021
- Influenza A Virus, H3N2 Subtype Infections - Dormant Projects, 2021
- Influenza A Virus, H3N2 Subtype Infections - Discontinued Products, 2021
List of Figures
- Number of Products under Development for Influenza A Virus, H3N2 Subtype Infections, 2021
- Number of Products under Development by Companies, 2021
- Number of Products under Development by Universities/Institutes, 2021
- Number of Products by Targets, 2021
- Number of Products by Stage and Targets, 2021
- Number of Products by Mechanism of Actions, 2021
- Number of Products by Stage and Mechanism of Actions, 2021
- Number of Products by Routes of Administration, 2021
- Number of Products by Stage and Routes of Administration, 2021
- Number of Products by Top 10 Molecule Types, 2021
- Number of Products by Stage and Top 10 Molecule Types, 2021
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- AbbVie Inc
- Adimmune Corp
- Alla Chem LLC
- Allergy Therapeutics Plc
- AlphaVax Inc
- Ansun Biopharma Inc
- Aphios Corp
- AstraZeneca Plc
- AusBio Ltd
- BiondVax Pharmaceuticals Ltd
- BlueWillow Biologics Inc
- Brandenburg Antiinfektiva GmbH
- Celltrion Inc
- Changchun Bcht Biotechnology Co Ltd
- Chicago Biosolutions Inc
- Cidara Therapeutics Inc
- CSL Ltd
- Emergent BioSolutions Inc
- FluGen Inc
- Gamma Vaccines Pty Ltd
- ILiAD Biotechnologies LLC
- Inovio Pharmaceuticals Inc
- Institute of Virology Vaccines and Sera Torlak
- InvVax Inc
- Jiangsu Ab&b Biotechnology Co Ltd
- Jiangsu Kanion Pharmaceutical Co Ltd
- Liaoning Cheng Da Biotechnology Co Ltd
- Medicago Inc
- NanoViricides Inc
- New Amsterdam Sciences Inc
- Novavax Inc
- PrEP Biopharm Ltd
- Sanofi
- Sciogen Inc
- Seqirus Ltd
- Serum Institute of India Pvt Ltd
- Shanghai Institute of Biological Products Co Ltd
- Trellis Bioscience Inc
- Vacthera BioTech GmbH